Additional file 1: of IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis

Figure S1. Effect of osteogenic differentiation on both Ct-BdCs and AS-BdCs. Figure S2. Correlation of IL-17 levels in AS patients with ESR, CRP, and BASDAI levels. Figure S3. Correlation of IL-17 levels in RA patients with ESR and CRP levels. Figure S4. Secukinumab inhibits AS serum-induced phosphorylation status of JAK2/STAT3 in Ct-BdCs. Figure S5. Secukinumab suppresses IL-17A dose-dependent ALP activation in Ct-BdCs. Figure S6. Effect of JAK2 inhibitor (AG490) treatment on viability and toxicity of both Ct- and AS-BdCs. Table S1. Primer Sequences for qPCR. Table S2. Primary antibodies used in Immunoblotting (IB), Immunostaining (IF), and Immunohistochemistry (IHC). (DOCX 826 kb)